Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0037 | 0.1203 | 0.36 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0054 | 0.224 | 0.224 |
Echinococcus granulosus | tar DNA binding protein | 0.0072 | 0.3342 | 1 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0017 | 0.0002 | 0.0005 |
Loa Loa (eye worm) | isocitrate dehydrogenase | 0.0017 | 0.0002 | 0.0002 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0072 | 0.3342 | 0.3342 |
Schistosoma mansoni | tar DNA-binding protein | 0.0072 | 0.3342 | 1 |
Brugia malayi | hypothetical protein | 0.0018 | 0.0033 | 0.0033 |
Echinococcus granulosus | NADP dependent isocitrate dehydrogenase | 0.0017 | 0.0002 | 0.0005 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0072 | 0.3342 | 0.3342 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0017 | 0.0002 | 0.0005 |
Echinococcus multilocularis | isocitrate dehydrogenase 2 (NADP+) | 0.0017 | 0.0002 | 0.0005 |
Brugia malayi | hypothetical protein | 0.0027 | 0.062 | 0.062 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.062 | 0.062 |
Echinococcus multilocularis | tar DNA binding protein | 0.0072 | 0.3342 | 1 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0017 | 0.0002 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0072 | 0.3342 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0072 | 0.3342 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 0.224 | 0.224 |
Schistosoma mansoni | tar DNA-binding protein | 0.0072 | 0.3342 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0.062 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0072 | 0.3342 | 0.3342 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.062 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.1203 | 0.1203 |
Schistosoma mansoni | NADP-specific isocitrate dehydrogenase | 0.0017 | 0.0002 | 0.0005 |
Schistosoma mansoni | tar DNA-binding protein | 0.0072 | 0.3342 | 1 |
Echinococcus multilocularis | isocitrate dehydrogenase | 0.0017 | 0.0002 | 0.0005 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0037 | 0.1203 | 0.1203 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.062 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0027 | 0.062 | 1 |
Onchocerca volvulus | 0.0182 | 1 | 0.5 | |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0054 | 0.224 | 0.224 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.062 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0027 | 0.062 | 1 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0017 | 0.0002 | 0.0005 |
Loa Loa (eye worm) | TAR-binding protein | 0.0072 | 0.3342 | 0.3342 |
Brugia malayi | RNA binding protein | 0.0072 | 0.3342 | 0.3342 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.062 | 1 |
Brugia malayi | Isocitrate dehydrogenase | 0.0017 | 0.0002 | 0.0002 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0027 | 0.062 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0054 | 0.224 | 0.224 |
Brugia malayi | isocitrate dehydrogenase | 0.0017 | 0.0002 | 0.0002 |
Brugia malayi | TAR-binding protein | 0.0072 | 0.3342 | 0.3342 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.5481 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 3.9811 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 63.0957 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.